Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda
Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda
复制标题
DOI:
10.1186/1475-2875-5-59
复制
发表时间:
2006-07-19
期刊:
影响因子:
3
通讯作者:
Guthmann, Jean-Paul
中科院分区:
文献类型:
--
作者:
Checchi, Francesco;Piola, Patrice;Guthmann, Jean-Paul
Background: A six-dose antimalarial regimen of artemether-lumefantrine (A/L) may soon become one of the most widely used drug combination in Africa, despite possible constraints with adherence and poor absorption due to inadequate nutrition, and a lack of pharmacokinetic and effectiveness data.Methods: Within a trial of supervised versus unsupervised A/L treatment in a stable Ugandan Plasmodium falciparum transmission setting, plasma lumefantrine concentrations were measured in a subset of patients on day 3 (C [lum](day3)) and day 7 (C [lum](day7)) post-inclusion. Predictors of lumefantrine concentrations were analysed to show how both C [lum](day7) and the weight-adjusted lumefantrine dose affect 28-day recrudescence and re-infection risks. The implications of these novel findings are discussed in terms of the emergence of lumefantrine-resistant strains in Africa.Results: C [lum](day3) and C [lum](day7) distributions among 241 supervised and 238 unsupervised patients were positively skewed. Unsupervised treatment and decreasing weight-adjusted lumefantrine dose were negatively associated with C [lum](day3). Unsupervised treatment and decreasing age showed strong negative associations with C [ lum] day7. Both models were poorly predictive (R-squared